News

Categories

May 1, 2023

Zymeworks Announces Participation In Upcoming Investor Conferences

April 18, 2023

Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting

April 17, 2023

Zymeworks To Host First Quarter 2023 Results Conference Call

April 10, 2023

Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors

April 3, 2023

Zymeworks Announces Participation In Upcoming Investor Conferences

March 14, 2023

Zymeworks To Present Updated Data On Multiple Product Candidates At The American Association For Cancer Research (AACR) Annual Meeting

March 7, 2023

Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results

February 28, 2023

Zymeworks Announces Participation In Upcoming Investor Conferences

February 21, 2023

Zymeworks To Host Fourth Quarter And Full Year 2022 Results Conference Call

January 25, 2023

Zymeworks Announces Participation In Upcoming Investor Conferences

January 19, 2023

Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma

January 17, 2023

Zymeworks Announces Abstract for Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma at the American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI)